Alfred Sandrock, Head of Research & Development at Biogen, holds 322.84K shares in Voyager Therapeutics (Ticker: VYGR), holds 10.17K shares in Biogen (Ticker: BIIB), holds 0.00 shares in Neurocrine (Ticker: NBIX). Most recently, Alfred Sandrock Sold ― shares of Voyager Therapeutics on Apr 03, 2024 for an estimated value of 119.45K.